Ultragenyx Pharmaceutical Inc. (RARE) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 2.27B |
| Enterprise Value | 3.11B |
| P/E Ratio | -4.42 |
| PEG Ratio | 0.71 |
| Price/Sales Ratio | 3.55 |
| Price/Book Ratio | -9.04 |
| Enterprise/Revenue | 5.05 |
| Enterprise/EBITDA | -7.66 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | June 30, 2026 |
Profitability
| Profit Margin | -0.82 |
| Operating Margin | -0.74 |
AD
Management Effectiveness
| Return On Assets | -0.46 |
| Return On Equity | 3.92 |
Income Statement
| Revenue | 673M |
| Revenue/Share | 7.04 |
| Gross Profit | 564M |
| EBITDA | -474M |
| Net Income | -575M |
| Diluted EPS | -5.83 |
Balance Sheet
| Total Cash | 292M |
| Total Cash/Share | 2.87 |
| Total Debt | 1.2B |
| Total Debt/Equity | -4.13 |
| Current Ratio | 1.73 |
| Book Value Per Share | -2.79 |
Price History
| 52-Week Change | -13.26 |
| 52-Week High | 39.89 |
| 52-Week Low | 18.29 |
| Moving Average 50 Days | 28.33 |
| Moving Average 200 Days | 26.42 |
Statistics
| Average Volume | 2.32M |
| Shares Outstanding | 98.49M |
| % Held by Institutions | 106.68 |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
